iTeos Therapeutics is developing next-generation immuno-oncology therapies to fight cancer. iTeos' platform is designed to identify and develop therapies that can activate and modulate the immune system to recognize and attack cancer cells. The company's therapies overcome the limitations of traditional immuno-oncology therapies, such as: limited efficacy (iTeos' therapies target multiple immune checkpoints and activate multiple immune cell types) and autoimmune side effects (iTeos' therapies are less toxic by targeting specific immune checkpoints and activating immune cells in a controlled manner).The company's lead product candidate is an anti-PD-1 and anti-TIGIT combination therapy for the treatment of non-small cell lung cancer.

iTeos Therapeutics

Founded: 2011
Location: Watertown, MA
Employee range: 11 - 50
Clinical stage: Clin2
Therapy area: Solid tumors
Drug types: ONC
Lead product: Inupadenant
Funding: $231M IPO Jul 2020; $100M B-2 Mar 2020; €15M Jan 2020; $75M B Jun 2018

Drug notes:

About:

Jobs: